Endeavor BioMedicines Closes $101M Series B Financing to Advance Clinical-Stage Precision Medicine Pipeline
February 7, 2022
© 2023 – Endeavor Biomedicines | Privacy Notice | Terms of Use
Endeavor BioMedicines Closes $101M Series B Financing to Advance Clinical-Stage Precision Medicine Pipeline
February 07, 2022
Endeavor Biomedicines doses first patient in phase 2 clinical trial of Taladegib (ENV-101) for idiopathic pulmonary fibrosis; appoints chief medical officer
September 22, 2021
Endeavor Biomedicines Licenses Ulk1/2 Inhibitor Program From Salk Institute And Sanford Burnham Prebys To Broaden Its Precision Oncology Pipeline
September 16, 2021
Endeavor Biomedicines Launches With $62 Million Series A Financing And Mission To Reverse The Course Of Devastating Pulmonary Disease
January 7, 2021